Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- 11 November 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (12), 1730-1739
- https://doi.org/10.1016/s1470-2045(19)30688-6
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen ReceptorsClinical Cancer Research, 2015
- Switching and withdrawing hormonal agents for castration-resistant prostate cancerNature Reviews Urology, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamideAnnals of Oncology, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialThe Lancet Oncology, 2012
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancerBJU International, 2005
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996